Abstract: Cinchonine, dihydrocinchonine or hydroquinidine are used as multidrug resistance inhibiting substance in the treatment of cancerous tumors by the use of cytotoxic agents. Particularly, cinchonine, dihydrocinchonine or hydroquinidine are used in the preparation of pharmaceutical compositions used in the treatment of cancerous tumors developing the phenomenon of multidrug resistance. Application to the treatment of human cancers.
Type:
Grant
Filed:
March 3, 1995
Date of Patent:
June 3, 1997
Assignee:
Debiopharm S.A.
Inventors:
Bruno Chauffert, Philippe Genne, Gilles Gutierrez, Rolland-Yves Mauvernay
Abstract: New biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula:RO--(CH.sub.2 --CH.sub.2 O).sub.n --(CO)--NH--X--(CO)--NH--Z (I)whereinR represents a lower alkyl group,n is an integer comprised between 25 and 250,X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, andZ when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH.sub.2 containing drug residue.
Type:
Grant
Filed:
January 7, 1993
Date of Patent:
February 15, 1994
Assignee:
Debiopharm, S.A.
Inventors:
Francesco Veronese, Luciana Sartore, Piero Orsolini, Romano Deghenghi
Abstract: A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.
Abstract: There is disclosed a pharaceutical composition for sustained and controlled release of drug over an extended period of time comprising a polylactide, a copolymer of lactic and glycolic acid, a mixture of such polymers and a water-insoluble peptide which, when placed in an aqueous physiologically-type environment releases the peptide in continuous manner for a period of at least one week, and with an initial release for the first twenty-four hours of not more than 30% of the total amount released. There is thus provided the control of the release pattern and in general a decrease of the initial burst effect.
Type:
Grant
Filed:
September 20, 1988
Date of Patent:
March 9, 1993
Assignee:
Debiopharm S.A.
Inventors:
Piero Orsolini, Rolland-Yves Mauvernay, Romano Deghenghi
Abstract: The pharmaceutical composition is intended in particular for the sustained and controlled release of an effective dose of a medicinal substance. It comprises, as a carrier for the medicinal substance, a biodegradable polymer or copolymer or a mixture of biodegradable polymers and/or copolymers derived from a dicarboxylic acid selected from the acids of the Krebs cycle, and from an aliphatic diol containing 4 carbon atoms or from cyclohexane-1,4-dimethanol.
Type:
Grant
Filed:
March 29, 1990
Date of Patent:
February 16, 1993
Assignee:
Debiopharm S.A.
Inventors:
Peter Speiser, Urs Schleuniger, Piero Orsolini, Frederic Heimgartner
Abstract: A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.
Abstract: Preparation containing hexatriacontapeptides suitable for intravenous administration to human or other animal subjects are disclosed. such compositions are effective in treating life-threatening hypotension as encountered in bacteremic, anaphylactic or cardiogenic shock.
Abstract: The antagonistic effect of the releasing hormone of LH and FSH or of one of its synthetic analogues selected from the group(pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2(pyro) Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH.sub.2and(pyro) Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR.sup.1(R.sup.1 being an alkyl group). On hormone-dependent diseases can be increased by coating such compounds by micro-encapsulation or by matrix formation with a copolymer of a lactide and a glycolide. The initial stimulating effect of the above-mentioned compounds is increased by this coating, with about 23 to 50% of the active principle of the analog being released within about 1-5 days after injection to a human, with the remainder released over a period of between about 3 weeks and two months.
Type:
Grant
Filed:
May 19, 1987
Date of Patent:
May 30, 1989
Assignee:
Debiopharm S.A.
Inventors:
Thomas R. Tice, Piero Orsolini, Andrew V. Schally
Abstract: The microencapsulation of medicamentous water-soluble substances is carried out by phase separation. The operations of the hardening step take place at a temperature comprised between about 0.degree. and about 25.degree. C., the non-solvent used during this step being an aliphatic fluorinated or fluorohalogenated hydrocarbon or a mixture of such hydrocarbons. Further, the non-solvent is used in an excess with respect to the volume of solvent and non-solvent resulting from the phase-separation step.
Type:
Grant
Filed:
October 15, 1985
Date of Patent:
June 16, 1987
Assignee:
Debiopharm, S.A.
Inventors:
Piero Orsolini, Rolland-Yves Mauvernay, Romano Deghenghi